Form 4: Beam Therapeutics Executive Sells Shares

Beam Therapeutics Chief Medical Officer Amy Simon reported a transaction involving the sale of 6,700 shares of common stock on April 1, 2026, to cover tax withholding obligations.

Summary

• Amy Simon, Chief Medical Officer at Beam Therapeutics Inc., engaged in a transaction on April 1, 2026.
• The transaction involved the sale of 6,700 shares of common stock at a price of $24.58 per share.
• These shares were sold automatically to cover tax withholding obligations upon the vesting of restricted stock units.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Ms. Simon on May 19, 2023.
• Following the transaction, Ms. Simon beneficially owns 102,735 shares of common stock.
• The filing also notes the acquisition of 183 shares on September 30, 2025, and 138 shares on March 31, 2026, under the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a stock sale by an executive, it is clearly explained as a pre-planned, non-discretionary transaction to cover tax obligations, which is a standard and expected event.

Positives

• The sale was conducted as part of a pre-arranged Rule 10b5-1 trading plan, indicating a structured and non-opportunistic approach to managing equity.
• The transaction was to cover tax withholding obligations, a standard procedure for executives upon vesting of equity awards.
• Ms. Simon continues to hold a significant number of shares (102,735) after the transaction.
• Additional shares were acquired through the Employee Stock Purchase Plan, demonstrating ongoing participation in company stock ownership.

Negatives

• A sale of company stock by a key executive, even if for tax purposes, can sometimes be perceived negatively by the market.
• The sale price of $24.58 per share represents a specific valuation point at the time of the transaction.

Risks

• The primary risk is the potential negative market perception of insider selling, regardless of the reason.
• Future vesting of restricted stock units could lead to further automatic sales if the Rule 10b5-1 plan remains active and tax obligations persist.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. However, the existence of a Rule 10b5-1 plan suggests potential for future automatic sales to cover tax obligations as more equity vests.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
• These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors regarding their stock transactions. The use of a Rule 10b5-1 plan is a common and accepted practice to manage potential insider trading concerns while allowing executives to diversify or cover tax liabilities.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor negative signal, though the explanation of tax withholding and Rule 10b5-1 plan mitigates significant concern.
• Employees: The transaction is unlikely to have a direct impact on employees, other than reinforcing the company's use of equity compensation and standard executive financial planning.
• Management: Demonstrates adherence to corporate governance best practices by utilizing a Rule 10b5-1 plan for equity transactions.

Next Steps

• Continued monitoring of Form 4 filings for any further transactions by Amy Simon or other Beam Therapeutics executives.
• Observation of future vesting schedules for restricted stock units and their potential impact on subsequent sales under the Rule 10b5-1 plan.

Key Dates

Keywords

Form 4, SEC Filing, Insider Transaction, Stock Sale, Beam Therapeutics, Amy Simon, Chief Medical Officer, Rule 10b5-1, Tax Withholding, Restricted Stock Units, Common Stock, Beneficial Ownership